Exploring the involvement of Adathoda vasica in hypoxia axis at the molecular level

The role of increased hypoxia has been identified for the many pathological features of SARS-CoV2, such as impaired immunity, airway hyper-inflammation, fibrosis, sepsis, and thrombosis. In this study, we tested the potential effect of Adhatoda Vasica (AV) aqueous extract, an ayurvedic anti-hypoxic, and anti-inflammatory medicine, on SARS-CoV2 infection using genome-wide expression approach. In this study, we did the genome-wide expression analysis of the lungs of mice treated with AV and compared them with transcriptome data of COVID19 patients. A meta-analysis of transcriptome profiles shows that AV may serve as a potential drug candidate to boost immune response and to prevent the transcriptional response elicited by SARS-CoV2 infection. For the transcriptomic experiment, distilled water (vehicle) or AV administered to naïve BALB/c mice by oral gavage for four consecutive days. Lung total RNA was isolated on 4th day of experiment, and a microarray experiment performed using Affymetrix Gene Chip MTA 1.0 array according to manufacturer’s instruction. Gene expression analysis was performed using Affymetrix® Expression Console and functional analysis done by using the Enrichr tool.